The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Potentially targetable alterations identified in circulating tumor DNA (ctDNA) from patients (pts) with advanced rare cancers.
 
Hitomi Sumiyoshi Okuma
No Relationships to Disclose
 
Kan Yonemori
Honoraria - AstraZeneca; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Novartis; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Yuki Kojima
No Relationships to Disclose
 
Maki Tanioka
Research Funding - Eisai
 
Kazuki Sudo
Honoraria - AstraZeneca
 
Emi Noguchi
Consulting or Advisory Role - Chugai Pharma; Lilly Japan
Speakers' Bureau - AstraZeneca; Pfizer; Sysmex
 
Susumu Hijioka
No Relationships to Disclose
 
Keiko Wakakuwa
No Relationships to Disclose
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Hitoshi Ichikawa
No Relationships to Disclose
 
Akihiro Hirakawa
Research Funding - Ono Pharmaceutical (Inst)
 
Aya Kuchiba
Honoraria - Chugai Pharma
 
Taro Shibata
No Relationships to Disclose
 
Tamie Sukigara
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Bayer Yakuhin; Chugai Pharma
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyorin (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Sysmex
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; Otsuka; PRA health science; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)